Histogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017
October 26 2017 - 8:30AM
Histogenics Corporation (Nasdaq:HSGX), a leading cell therapy
company focused on developing and commercializing products in the
musculoskeletal space, announced it will report its third quarter
2017 financial results on Thursday, November 9, 2017 before the
U.S. financial markets open. The Company will host a
conference call and webcast at 8:30 a.m. ET to review financial and
operational results for the quarter ended September 30, 2017 and
provide a company update.
To access the live call, please dial
877-930-8064 (domestic) or 253-336-8040 (international) and provide
the conference ID: 89009539. Please log in five to ten
minutes before the start of the call.
A live audio webcast of the presentation will be
available via the “Investor Relations” page of the Histogenics
website, www.histogenics.com, or by clicking here. A replay
of the webcast will be archived on Histogenics’ website for
approximately 45 days following the presentation.
About Histogenics
Corporation
Histogenics is a leading cell therapy company
developing and commercializing novel tissue therapies that may
offer more rapid and durable recoveries for patients with pain and
loss of function due to musculoskeletal conditions.
Histogenics’ regenerative medicine platform combines
expertise in cell processing, scaffolding, tissue engineering and
bioadhesives to create tissue ex-vivo. Histogenics’ first
investigational product candidate, NeoCart® is designed to treat
cartilage defects in the knee. The Company recently completed
enrollment of its NeoCart Phase 3 clinical trial and expects to
report top-line data in the third quarter of 2018. NeoCart is
designed to exhibit characteristics of articular, hyaline cartilage
prior to and upon implantation into the knee and therefore does not
rely on the body to make new cartilage. As a result, NeoCart
is the only product in development or on the market with a one-year
primary superiority endpoint as compared to the standard of
care. There are more than 500,000 or more knee cartilage
procedures in the United States each year, with many healthy active
adults avoiding treatment as they seek other alternatives.
Left untreated, even a small cartilage defect can expand in
size and progress to debilitating osteoarthritis, ultimately
necessitating a joint replacement procedure. Osteoarthritis
is more common in adults over the age of 50, but the condition and
precursors of the condition can be observed much earlier, and
cartilage damage is believed to be one of the leading contributors
of this disease. For more information, please visit
www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Sep 2023 to Sep 2024